A phase II study of XILONIX (MABp1) in patients with non-small cell lung cancer

Trial Profile

A phase II study of XILONIX (MABp1) in patients with non-small cell lung cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Erlotinib (Primary) ; MABp1 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 New trial record
    • 11 Dec 2015 According to a company media release, XBiotech plans to initiate this study in the Q2 2016. The study is a follow up of results from a phase I study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top